Do gender and race impact the use of antithrombotic therapy in patients with stroke/TIA?
The authors examined the relationships between sex and race and antithrombotics prescribed at discharge in the Michigan Medicare population using retrospective medical record abstraction (n = 2,715) for the period January 1, 2001, to June 30, 2001. There were no differences in the use of antithrombotics at discharge by race or sex and no differences in the prescribing of aspirin, warfarin, aspirin/extended release dipyridamole, or clopidogrel by race or sex after adjustment for confounders.
Lisabeth
Lynda D
LD
Stroke Program, University of Michigan Health System, Ann Arbor, MI 48109-0489, USA. llisabet@umich.edu
Roychoudhury
Canopy
C
Brown
Devin L
DL
Levine
Steven R
SR
D001741:Black or African American / Q000706:statistics & numerical data*; D000368:Aged; D000369:Aged, 80 and over; D015897:Comorbidity; D004363:Drug Utilization / Q000706:statistics & numerical data; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D002546:Ischemic Attack, Transient / Q000188:drug therapy* / Q000453:epidemiology; D008297:Male; D006278:Medicare; D008824:Michigan; D010351:Patient Discharge; D020521:Stroke / Q000188:drug therapy* / Q000453:epidemiology; D015912:Thrombolytic Therapy / Q000706:statistics & numerical data*; D044465:White People / Q000706:statistics & numerical data*
D005343:Fibrinolytic Agents